Amy Boggs
Psychiatric/Mental Health · Norman, OKNPI 1629370291
Payments from drug & device makers
Across 898 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- plus $5K from 25 others
What the payments were for
- Food & beverage$15,301100%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 126 | $2,308 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 131 | $2,205 |
| AbbVie | 136 | $1,550 |
| Johnson & Johnson | 98 | $1,440 |
| Otsuka America Pharmaceutical, Inc. | 74 | $1,437 |
| Neurocrine Biosciences, Inc. | 58 | $1,131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 60 | $1,034 |
| Alkermes, Inc. | 47 | $850 |
| Sunovion Pharmaceuticals Inc. | 36 | $584 |
| Corium, LLC | 26 | $515 |
| Supernus Pharmaceuticals, Inc. | 14 | $437 |
| E.r. Squibb & Sons, L.L.C. | 14 | $362 |
| Axsome Therapeutics, Inc. | 14 | $285 |
| Lundbeck LLC | 12 | $254 |
| Idorsia Pharmaceuticals US Inc | 9 | $161 |
| Vanda Pharmaceuticals Inc. | 7 | $147 |
| Almatica Pharma LLC | 8 | $142 |
| Eisai Inc. | 6 | $111 |
| Merck | 4 | $62 |
| Adlon Therapeutics L.p. | 3 | $49 |
| Noven Therapeutics, LLC | 2 | $43 |
| Neos Therapeutics, LP | 2 | $34 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Ironshore Pharmaceuticals Inc. | 2 | $29 |
| Indivior Inc. | 1 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $19 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,348 in reported general payments places this provider in the 95th percentile of 231 psychiatric/mental health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 51 | $458,583 |
| IngrezzaValbenazine Tosylate | 12 | $102,756 |
| SpravatoEsketamine Hcl | 16 | $47,466 |
| VraylarCariprazine Hcl | 28 | $39,784 |
| TrintellixVortioxetine Hydrobromide | 15 | $15,383 |
| QuviviqDaridorexant Hcl | 13 | $6,450 |
| Lurasidone Hcl | 39 | $6,093 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 70 | $4,520 |
| Duloxetine Hcl | 132 | $3,893 |
| Quetiapine Fumarate | 160 | $3,353 |
| Lamotrigine | 171 | $2,355 |
| Bupropion XlBupropion Hcl | 97 | $2,287 |
| Oxcarbazepine | 50 | $2,153 |
| Buspirone Hcl | 160 | $1,961 |
| Chlorpromazine Hcl | 12 | $1,745 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,308 | $458,58351 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,131 | $102,75612 claims |
| Johnson & JohnsonSpravato | $1,440 | $47,46616 claims |
| AbbVieVraylar | $1,550 | $39,78428 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,034 | $15,38315 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $161 | $6,45013 claims |
| Almatica Pharma LLCSertraline Hcl | $142 | $1,22381 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 231 psychiatric/mental health providers in Oklahoma.
Other psychiatric/mental health in Norman
- Nicole HolzerNorman$12K
- Laura HallNorman$10K
- Melissa BelangerNorman$10K
- Paula RotherNorman$9K
- Teresa ShermanNorman$8K
- Vallie CopleyNorman$6K
- Renate WinninghamNorman$6K
- Enieni OkoyaNorman$5K
- Craig PattonNorman$3K
- Meryl AaronEdmond$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.